Mutations of KRAS4B are particularly prevalent in cancer, comprising ∼80% of all RAS-related oncogenic mutations (Downward, 2003; Hancock, 2003; Cox et al., 2014; Cox et al., 2015; Prior et al., 2020). Here, KRAS is linked to cancer.